home / stock / apto / apto quote
Last: | $0.7418 |
---|---|
Change Percent: | -3.69% |
Open: | $0.7876 |
Close: | $0.7418 |
High: | $0.7998 |
Low: | $0.7396 |
Volume: | 35,569 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.7418 | $0.7876 | $0.7418 | $0.7998 | $0.7396 | 35,569 | 07-05-2024 |
$0.7596 | $0.779 | $0.759551 | $0.81 | $0.7205 | 19,671 | 07-04-2024 |
$0.759551 | $0.779 | $0.759551 | $0.81 | $0.7205 | 19,671 | 07-03-2024 |
$0.743 | $0.779 | $0.743 | $0.7796 | $0.7401 | 15,990 | 07-02-2024 |
$0.745 | $0.7738 | $0.745 | $0.8 | $0.733 | 39,381 | 07-01-2024 |
$0.759 | $0.769 | $0.759 | $0.769 | $0.7311 | 13,070 | 06-28-2024 |
$0.75 | $0.76 | $0.75 | $0.76 | $0.74 | 14,942 | 06-27-2024 |
$0.744091 | $0.81 | $0.744091 | $0.81 | $0.73 | 39,227 | 06-26-2024 |
$0.74 | $0.761 | $0.74 | $0.781362 | $0.7101 | 57,469 | 06-25-2024 |
$0.742 | $0.8 | $0.742 | $0.808 | $0.732 | 41,891 | 06-24-2024 |
$0.76 | $0.792 | $0.76 | $0.8563 | $0.74 | 86,285 | 06-21-2024 |
$0.7996 | $0.84 | $0.7996 | $0.84 | $0.78 | 73,793 | 06-20-2024 |
$0.837 | $0.88 | $0.837 | $0.8999 | $0.8351 | 51,258 | 06-19-2024 |
$0.837 | $0.88 | $0.837 | $0.8999 | $0.8351 | 51,258 | 06-18-2024 |
$0.87 | $0.9059 | $0.87 | $0.926 | $0.87 | 92,327 | 06-17-2024 |
$0.89 | $0.94 | $0.89 | $1 | $0.8501 | 133,314 | 06-14-2024 |
$0.93 | $0.91 | $0.93 | $1.08 | $0.91 | 245,121 | 06-13-2024 |
$0.91 | $0.91 | $0.91 | $0.94 | $0.87 | 51,491 | 06-12-2024 |
$0.88 | $0.92 | $0.88 | $0.9399 | $0.88 | 78,603 | 06-11-2024 |
$0.91 | $0.91 | $0.91 | $0.94 | $0.87 | 41,274 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...
SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...